

P9185 Project 1: Protocol of a Phase II MATIK Trial

Kate Colvin, Chhiring Lama, Emily Carter

Contents

I. Introduction	1
II. Methods	1
III. Results	2
3.1 Primary Objective 1	2
GLMM	2
3.2 Primary Objective 2	7
3.3 Secondary Objective 1	10
3.4 Secondary Objective 2	16
IV. Discussion	18
V. Conclusion	18
VI. Appendix	19

I. Introduction

II. Methods


Notation:

k :subject, $k = 1, \dots, 180$
 j :sequence, $j = 0, 1, 2$
 i :period, $i = 1, 2, 3$
 h :week, $h = 1, 2, 3, 4$
 π :period effect
 τ :treatment effect
 α :grouped treatment effects
 β :demographic effects
 λ :sequence/carryover effect
 γ :week effect
 b :subject-specific intercepts
 μ :fixed-effect intercept
 ε :residual error

III. Results

3.1 Primary Objective 1

Proportion of Adverse Events per period



Patient Distribution: 30 people in per treatment sequence Initial Observation: Most patients do not face adverse events over the course of 4 weeks in each of the consecutive periods.

add demographic data

demographic summary

Table 1: Distributional Summary of Predictor variables in the Study

Characteristic	period1			period2			period3		
	No N = 164	Yes N = 16	p-value	No N = 168	Yes N = 12	p-value	No N = 163	Yes N = 17	p-value
age	31 (25, 37)	42 (40, 44)	<0.001	32 (25, 38)	40 (37, 44)	<0.001	32 (25, 38)	38 (32, 42)	0.012

¹ Median (Q1, Q3)

² Wilcoxon rank sum test

GLMM

Model Selection

Characteristic	OR	95% CI	p-value
(Intercept)	0.00	0.00, 0.00	<0.001
Treatment			
Pill A	—	—	
Gel B	1.20	0.55, 2.64	0.6
Gel C	0.84	0.37, 1.92	0.7
Period			
period1	—	—	
period2	0.71	0.31, 1.64	0.4
period3	1.13	0.52, 2.46	0.8
Treatment Sequence			
ABC or BAC	—	—	
CAB or ACB	0.61	0.23, 1.62	0.3
BCA or CBA	0.84	0.35, 2.02	0.7
age	1.19	1.11, 1.27	<0.001
gender			
Female	—	—	
Male	0.90	0.43, 1.89	0.8
race			
black	—	—	
others	1.55	0.61, 3.95	0.4
white	1.74	0.65, 4.68	0.3

Abbreviations: CI = Confidence Interval, OR = Odds Ratio

Table 2: LRT Between Model w/ and w/o Interaction Between Tx and Period

term	npars	AIC	BIC	logLik	deviance	statistic	df	p.value
glmm2	12	278.67	330.17	-127.34	254.67	NA	NA	NA
glmm1	16	281.34	350.01	-124.67	249.34	5.33	4	0.25

Table 3: LRT Between Model w/ and w/o Race, Gender and Carryover Effect

term	npars	AIC	BIC	logLik	deviance	statistic	df	p.value
glmm3	7	271.25	301.29	-128.62	257.25	NA	NA	NA
glmm2	12	278.67	330.17	-127.34	254.67	2.57	5	0.77

Characteristic	OR	95% CI	p-value
(Intercept)	0.00	0.00, 0.00	<0.001
Treatment			
Pill A	—	—	
Gel B	1.18	0.54, 2.58	0.7
Gel C	0.85	0.37, 1.94	0.7
Period			
period1	—	—	
period2	0.72	0.31, 1.65	0.4
period3	1.11	0.51, 2.40	0.8
age	1.19	1.12, 1.27	<0.001

Abbreviations: CI = Confidence Interval, OR = Odds Ratio

Model Result (with Carryover Effect)


Final Model Result (without Carryover Effect)

Notation:

$$\widehat{\text{logit}}(P(AE_{ijk} = 1)) = b_k + \mu + \tau_i + \pi_j + \beta a_k,$$


$$i = 1, 2, 3, j = 1, 2, 3, k = (1, 2, \dots, 180),$$

$$b_k \sim N(0, \sigma_b^2)$$




AE Prediction

Distribution of OR for Adverse Events




Predicted probabilities of adverse event



Model Diagnostics


Posterior Predictive Check

Model-predicted intervals should include observed data points




Binned Residuals

Points should be within error bounds




Influential Observations

Points should be inside the contour lines




Collinearity

High collinearity (VIF) may inflate parameter uncertainty




Distribution of Quantile Residuals

Dots should fall along the line




Normality of Random Effects (ptid)



Dots should be plotted along the line



3.2 Primary Objective 2

Individual Patient Adherence Over Time, by Treatment





Model

\$\$

$$Y_{hik} \sim \text{Binomial}(n = 7, p_{hik}), \quad (1)$$

$$\text{logit}(p_{hik}) = \mu + b_k + \pi_i + \tau_i + \lambda_j + \gamma * h, \quad (2)$$

$$b_k \sim \mathcal{N}(0, \sigma_b^2) \quad (3)$$


\$\$

Table 4: GLMM Results of Treatment on Adherence

Characteristic	OR	95% CI	p-value
Treatment			
Pill A	—	—	
Gel B	0.14	0.12, 0.17	<0.001
Gel C	0.21	0.17, 0.24	<0.001
Week	0.73	0.69, 0.76	<0.001
Period			
1	—	—	
2	1.15	1.00, 1.32	0.051
3	1.05	0.92, 1.20	0.5


Abbreviations: CI = Confidence Interval, OR = Odds Ratio

DHARMA residual



3.3 Secondary Objective 1

EDA: Blood VL




EDA: Skin VL

Table 5: Linear mixed-effects model results examining change in blood and skin viral loads (baseline minus end of period) by treatment group, adverse event status, study period, and baseline viral load. Results show beta coefficients, 95% confidence intervals, and p-values for each predictor.







Comparison	Blood Viral Load			Skin Viral Load		
	Beta	95% CI	p-value	Beta	95% CI	p-value
Intercept	14.6	6.2, 23.1	<0.001	45.0	25.9, 64.0	<0.001
Treatment						
Gel B vs Pill A	-9.8	-12.5, -7.0	<0.001	-31.7	-36.9, -26.5	<0.001
Gel C vs Pill A	-12.1	-14.8, -9.4	<0.001	-41.5	-46.7, -36.3	<0.001
Adverse Event						
Adverse Event	-21.0	-25.6, -16.5	<0.001	-44.8	-53.5, -36.1	<0.001
Period						
Period 2 vs Period 1	-1.4	-4.1, 1.3	0.3	-1.0	-6.2, 4.3	0.7
Period 3 vs Period 1	-1.5	-4.2, 1.2	0.3	0.4	-4.8, 5.7	0.9
Baseline Blood VL	0.9	0.8, 1.0	<0.001			
Baseline Skin VL				0.8	0.7, 0.9	<0.001

Abbreviation: CI = Confidence Interval



Safety Mixed Models

Model Diagnostics: Blood VL




Model Diagnostics: Skin VL

Table 6: Linear mixed-effects model results examining change in blood and skin viral loads (baseline minus end of period) by treatment group, adverse event status, study period, and baseline viral load. Results show beta coefficients, 95% confidence intervals, and p-values for each predictor.



Comparison	Blood Viral Load			Skin Viral Load		
	Beta	95% CI	p-value	Beta	95% CI	p-value
Intercept	-31.8	-43.1, -20.5	<0.001	-45.7	-71.4, -20.1	<0.001
Treatment						
Gel B vs Pill A	-4.4	-7.5, -1.3	0.005	-22.0	-27.9, -16.1	<0.001
Gel C vs Pill A	-7.7	-10.7, -4.7	<0.001	-33.2	-39.0, -27.5	<0.001
Additional Day of Adherence	1.4	1.1, 1.6	<0.001	2.5	2.0, 3.0	<0.001
Period						
Period 2 vs Period 1	-1.2	-4.1, 1.7	0.4	-0.8	-6.4, 4.7	0.8
Period 3 vs Period 1	-1.6	-4.5, 1.3	0.3	0.1	-5.5, 5.7	>0.9
Baseline Blood VL	1.0	0.9, 1.0	<0.001			
Baseline Skin VL				0.9	0.8, 1.0	<0.001

Abbreviation: CI = Confidence Interval





Adherence Mixed Models



Model Diagnostics: Blood VL









Red line = Normal(0,1), Blue line = Kernel density




Red line = Normal fit, Green line = Kernel density




Model Diagnostics: Skin VL



3.4 Secondary Objective 2





Model

\$\$

$$Y_{hik} \sim \text{Binomial}(n = 7, p_{hik}), \quad (4)$$


$$\text{logit}(p_{hik}) = \mu + b_k + \pi_i + \lambda_j + \gamma * h + \beta_d * d_k + \beta_r * regimen + \beta_p * product \quad (5)$$

$$+ \beta_{dr} * d_k * regimen + \beta_{dp} * d_k * product \quad (6)$$

$$b_k \sim \mathcal{N}(0, \sigma_b^2) \quad (7)$$

\$\$

DHARMA residual



IV. Discussion

V. Conclusion

VI. Appendix

Table 7: Interaction Results of Demographic Variables on Adherence

Characteristic	OR	95% CI	p-value
Age	1.21	1.18, 1.24	<0.001
Product			
Gel	—	—	
Pill	4.35	2.98, 6.35	<0.001
Gender			
Male	—	—	
Female	1.36	0.95, 1.95	0.10
Race			
white	—	—	
black	1.02	0.65, 1.60	>0.9
others	0.97	0.62, 1.53	0.9
Regimen			
once	—	—	
three	0.76	0.58, 1.00	0.050
Period			
1	—	—	
2	1.14	0.99, 1.32	0.073
3	1.03	0.89, 1.18	0.7
Week	0.73	0.69, 0.76	<0.001
Age * Product			
Age * Pill	1.00	0.97, 1.03	>0.9
Product * Gender			
Pill * Female	1.00	0.71, 1.40	>0.9
Product * Race			
Pill * black	1.23	0.81, 1.86	0.3
Pill * others	1.05	0.69, 1.61	0.8
Age * Regimen			
Age * three	1.02	1.00, 1.04	0.074
Gender * Regimen			
Female * three	0.89	0.69, 1.15	0.4
Race * Regimen			
black * three	1.14	0.84, 1.56	0.4
others * three	1.02	0.74, 1.41	0.9

Abbreviations: CI = Confidence Interval, OR = Odds Ratio

Table 8: Main Effect Results of Demographic Variables on Adherence

Characteristic	OR	95% CI	p-value
Age	1.22	1.19, 1.25	<0.001
Gender			
Male	—	—	
Female	1.29	0.92, 1.80	0.14
Race			
white	—	—	
black	1.11	0.73, 1.69	0.6
others	0.99	0.65, 1.50	>0.9
Regimen			
once	—	—	
three	0.71	0.63, 0.80	<0.001
Product			
Gel	—	—	
Pill	4.84	4.12, 5.70	<0.001
Period			
1	—	—	
2	1.14	0.99, 1.32	0.065
3	1.04	0.91, 1.20	0.6
Week	0.73	0.69, 0.76	<0.001

Abbreviations: CI = Confidence Interval, OR = Odds Ratio